GO:0098906 regulation of Purkinje myocyte action potential: Cardiac Conduction, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0098906 describes any process that modulates the frequency, rate or extent of action potential creation, propagation or termination in a Purkinje myocyte, typically via modulation of voltage-gated ion channels.
• Purkinje myocytes are specialized cardiac conduction cells whose action potentials determine the timing and synchrony of ventricular activation.
• The Purkinje-myocardial junction is an anatomic origin of ventricular arrhythmia in catecholaminergic polymorphic ventricular tachycardia (CPVT).
• Voltage-gated potassium currents in Purkinje cells are subject to Notch-mediated epigenetic regulation, linking developmental signaling to electrical remodeling.
• TRPM4 overexpression can cause propagation failure of action potentials, illustrating how non-selective cation channels modulate conduction.
• Calcium-channel blockers and phosphodiesterase 5 inhibitors are pharmacological tools that modulate action potential-related ion channel activity.
Description
The Gene Ontology term GO:0098906, regulation of Purkinje myocyte action potential, defines any process that modulates the frequency, rate or extent of action potential creation, propagation or termination in a Purkinje myocyte. Purkinje myocytes form the specialized ventricular conduction system that ensures rapid, coordinated electrical activation of the heart, and their action potentials are shaped by a distinct complement of voltage-gated ion channels. Understanding how these action potentials are regulated is therefore central to cardiac electrophysiology and to the mechanistic dissection of arrhythmia syndromes. The term is used by researchers to annotate gene products that influence Purkinje cell excitability, repolarization, or conduction velocity, including ion channels, signaling molecules, and epigenetic regulators. Because Purkinje myocytes are the anatomic origin of ventricular arrhythmia in CPVT, regulatory mechanisms within these cells are directly relevant to inherited and acquired arrhythmias. Experimental approaches such as single-cell voltage clamp have historically defined the ionic currents underlying cardiac action potentials, including those of Purkinje cells. More recently, multimodal pharmacological studies have highlighted how modulation of cyclic nucleotide signaling can influence neuronal and cardiac excitability. This article synthesizes the QuickGO definition with verified literature to provide a research-grade overview of GO:0098906, its mechanisms, associated genes, disease links, and CRISPR-based research models.
regulation of Purkinje myocyte action potential At A Glance
| GO ID | GO:0098906 |
|---|---|
| GO term | regulation of Purkinje myocyte action potential |
| Ontology | biological_process |
| Synonym | none |
| Major function | Modulation of action potential creation, propagation or termination in Purkinje myocytes, typically via voltage-gated ion channels |
| Cell type | Purkinje myocyte (specialized cardiac conduction cell) |
| Key molecular players | Voltage-gated ion channels, TRPM4, KIR2.1, Notch signaling components |
| Disease relevance | Ventricular arrhythmia, CPVT, conduction disorders |
| Research methods | Voltage clamp, patch clamp, CRISPR models, transcriptomics |
What Is GO:0098906?
GO:0098906 is a biological process term defined as any process that modulates the frequency, rate or extent of action potential creation, propagation or termination in a Purkinje myocyte. This typically occurs via modulation of the activity or expression of voltage-gated ion channels. In practice, the term covers signaling events, channel regulation, and epigenetic or transcriptional control that alter Purkinje cell excitability and conduction.
Why Is regulation of Purkinje myocyte action potential Important in Cell Biology?
GO:0098906 is important because Purkinje myocytes are the final common pathway for ventricular activation, and their action potential regulation determines whether electrical impulses propagate faithfully or degenerate into arrhythmia. The Purkinje-myocardial junction is a documented anatomic origin of ventricular arrhythmia in CPVT, making regulatory mechanisms in these cells a direct therapeutic target. Moreover, epigenetic regulation of voltage-gated potassium currents in Purkinje cells demonstrates that electrical phenotype is not fixed but can be remodeled by developmental signaling pathways. Pharmacological modulation of ion channels and cyclic nucleotide signaling further underscores the translational relevance of this process.
• Purkinje myocyte action potentials ensure rapid, synchronous ventricular activation.
• Dysregulation at the Purkinje-myocardial junction can initiate ventricular arrhythmia in CPVT.
• Voltage-gated potassium currents in Purkinje cells are epigenetically regulated by Notch signaling.
• TRPM4 overexpression can cause action potential propagation failure.
• KIR2.1 channels contribute to cardiac electrical signaling and are linked to disease.
• Calcium-channel blockers modulate cardiac action potentials and are used clinically.
• Phosphodiesterase 5 inhibitors can influence cyclic nucleotide signaling relevant to excitability.
• Single-cell voltage clamp has been foundational for understanding cardiac action potentials.
• Computational neuroscience approaches help model Purkinje cell excitability.
• CRISPR-based models enable causal testing of candidate regulators in Purkinje-like cells.
What Happens During regulation of Purkinje myocyte action potential?
Ion channel expression and membrane excitability
In simple terms: Purkinje cells build their electrical identity by expressing specific ion channels.
The action potential of a Purkinje myocyte depends on the coordinated activity of voltage-gated ion channels that set resting potential, upstroke, plateau, and repolarization. Regulation of this process includes transcriptional and epigenetic control of channel expression, as shown for voltage-gated potassium currents in Purkinje cells where Notch signaling mediates epigenetic regulation. KIR2.1 channels are key contributors to cardiac electrical signaling and are subject to cellular regulation.
Action potential propagation and conduction failure
In simple terms: Sometimes the electrical signal fails to travel, and this is a regulated phenomenon.
Propagation of the action potential from Purkinje cells to myocardium can fail under certain conditions. TRPM4 overexpression has been shown to cause propagation failure, indicating that non-selective cation channels can modulate conduction. This highlights that regulation of Purkinje myocyte action potential includes mechanisms that determine whether propagation succeeds or fails.
Calcium and cyclic nucleotide signaling
In simple terms: Calcium and cyclic nucleotides tune the electrical behavior of heart cells.
Calcium-channel blockers act on basic cellular mechanisms of cardiac action potentials, affecting calcium entry and thereby excitability. Phosphodiesterase 5 inhibitors modulate cyclic nucleotide signaling, which can influence ion channel activity and neuronal/cardiac excitability. These pathways represent regulatory inputs that can alter Purkinje myocyte action potential properties.
Purkinje-myocardial junction and arrhythmia origin
In simple terms: The junction between Purkinje cells and heart muscle is a hotspot for arrhythmia.
The Purkinje-myocardial junction is the anatomic origin of ventricular arrhythmia in CPVT, demonstrating that regulation of action potentials at this site is clinically critical. This junction is where Purkinje cell action potentials must reliably trigger myocardial activation, and failure of regulation here can initiate arrhythmias.
Computational and electrophysiological characterization
In simple terms: Scientists use math and electrodes to understand these cells.
Computational neuroscience approaches have been applied to understand Purkinje cell excitability and network behavior. Single-cell voltage clamp has been instrumental in defining the ionic currents underlying cardiac action potentials, including those in Purkinje cells. These methods allow researchers to quantify how regulatory changes alter action potential parameters.
Key Genes Involved in GO:0098906 regulation of Purkinje myocyte action potential
The following genes and proteins are directly implicated in the regulation of Purkinje myocyte action potential or in related cardiac electrical signaling based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TRPM4 | Non-selective cation channel; overexpression causes propagation failure | Models of conduction block and arrhythmia |
| KCNJ2 (KIR2.1) | Inward rectifier potassium channel; regulates cardiac electrical signaling | Disease-linked channel; drug target |
| NOTCH1 | Signaling receptor mediating epigenetic regulation of voltage-gated potassium currents | Links developmental signaling to electrical remodeling |
| CACNA1C | Voltage-gated calcium channel; target of calcium-channel blockers | Pharmacological modulation of action potentials |
| SCN5A | Voltage-gated sodium channel; underlies action potential upstroke | Cardiac excitability research |
| KCNH2 (hERG) | Voltage-gated potassium channel; repolarization | Arrhythmia and drug safety |
| KCNQ1 | Voltage-gated potassium channel; repolarization | Long QT syndrome research |
| PDE5 | Phosphodiesterase; regulates cyclic GMP signaling | Modulates excitability via cyclic nucleotides |
| RYR2 | Ryanodine receptor; calcium release | CPVT and Purkinje-myocardial junction arrhythmia |
| CASQ2 | Calsequestrin; calcium buffering | CPVT-related calcium handling |
| HCN4 | Hyperpolarization-activated cyclic nucleotide-gated channel | Pacemaking and conduction |
| ATP1A1 | Na+/K+-ATPase; maintains ionic gradients | Action potential maintenance |
| ATP2A2 (SERCA2) | Calcium pump; regulates calcium reuptake | Excitation-contraction coupling |
| CACNB2 | Calcium channel auxiliary subunit | Modulates calcium current |
| KCNE1 | Potassium channel auxiliary subunit | Repolarization regulation |
| GJA1 (Connexin 43) | Gap junction protein; propagation | Conduction velocity research |
| GJA5 (Connexin 40) | Gap junction protein; Purkinje conduction | Specialized conduction system |
How Is regulation of Purkinje myocyte action potential Regulated?
Regulation of Purkinje myocyte action potential is itself regulated at multiple levels. Notch signaling mediates epigenetic regulation of voltage-gated potassium currents, thereby altering the electrical phenotype of Purkinje cells. Cyclic nucleotide signaling, including phosphodiesterase 5 activity, can modulate ion channel function and excitability. Calcium-channel blockers directly regulate calcium entry, affecting action potential shape and duration. Additionally, KIR2.1 channel function is subject to cellular regulation, including trafficking and modulation by signaling molecules. These layers of regulation allow dynamic control of conduction and repolarization.
regulation of Purkinje myocyte action potential and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RYR2 | CPVT; Purkinje-myocardial junction arrhythmia | Knock-in of CPVT mutation in Purkinje-like cells |
| TRPM4 | Propagation failure; conduction block | Overexpression in cardiac conduction cell models |
| KCNJ2 | Andersen-Tawil syndrome; arrhythmia | Knockout or point mutation in cardiomyocytes |
| NOTCH1 | Electrical remodeling; epigenetic regulation | Knockout in Purkinje cell models |
| CACNA1C | Timothy syndrome; long QT | Point mutation knock-in in iPSC-derived cardiomyocytes |
Catecholaminergic polymorphic ventricular tachycardia (CPVT)
The Purkinje-myocardial junction is the anatomic origin of ventricular arrhythmia in CPVT, a disease caused by mutations in calcium handling genes such as RYR2 and CASQ2. Regulation of Purkinje myocyte action potential is therefore directly implicated in the initiation of arrhythmias in CPVT.
Conduction block and propagation failure
TRPM4 overexpression can cause propagation failure of action potentials, suggesting that dysregulation of non-selective cation channels may contribute to conduction block. This links GO:0098906 to clinical scenarios of impaired ventricular conduction.
Channelopathies and arrhythmia syndromes
Voltage-gated ion channels such as KIR2.1, hERG, and SCN5A are associated with cardiac electrical diseases. Epigenetic regulation of potassium currents by Notch signaling further suggests that acquired changes in channel expression can contribute to arrhythmogenesis.
Pharmacological modulation and drug safety
Calcium-channel blockers and phosphodiesterase 5 inhibitors modulate pathways relevant to action potential regulation, with implications for therapeutic use and drug safety. Understanding GO:0098906 helps predict off-target effects of drugs on cardiac conduction.
From regulation of Purkinje myocyte action potential-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene alter Purkinje action potential duration? | Knockout in iPSC-derived Purkinje-like cells |
| Does a specific channel mutation reproduce CPVT phenotype? | Point mutation knock-in in RYR2 |
| Can overexpression of TRPM4 induce propagation failure? | Overexpression in cardiac conduction cell line |
| Does Notch signaling regulate potassium current expression? | Knockout or knockdown of NOTCH1 in Purkinje cells |
| Can a tagged channel be used to track trafficking? | Tagged knock-in of KCNJ2 |
| Does a drug modulate action potential parameters? | Pharmacological testing in voltage-clamped Purkinje myocytes |
How to Study the regulation of Purkinje myocyte action potential Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Patch clamp | Ion channel currents and action potentials | Quantify effects of gene knockout or drugs |
| Voltage clamp | Membrane current kinetics | Define ionic basis of action potential |
| RNA-seq | Gene expression changes | Identify channel expression changes after perturbation |
| ChIP-seq | Chromatin modifications and transcription factor binding | Study epigenetic regulation of potassium currents |
| Computational modeling | Simulated action potential and conduction | Predict effects of regulatory changes |
| Calcium imaging | Intracellular calcium transients | Assess calcium handling in Purkinje cells |
| Pharmacological assays | Drug effects on excitability | Test calcium-channel blockers or PDE5 inhibitors |
Electrophysiology (voltage clamp and patch clamp)
Single-cell voltage clamp has been foundational for understanding cardiac action potentials, including those of Purkinje myocytes. Patch clamp allows direct measurement of ion channel currents and the effects of regulatory interventions.
Transcriptomics and epigenomics
RNA-seq and epigenetic profiling can reveal changes in ion channel expression and chromatin state, as demonstrated for Notch-mediated epigenetic regulation of potassium currents. These methods help identify regulatory mechanisms upstream of action potential changes.
Computational modeling
Computational neuroscience approaches, including biophysical modeling, are used to simulate Purkinje cell excitability and predict the consequences of regulatory changes. Such models integrate ion channel kinetics with network behavior.
Pharmacological profiling
Calcium-channel blockers and phosphodiesterase 5 inhibitors are used to probe the roles of calcium and cyclic nucleotide signaling in action potential regulation. Dose-response experiments can quantify effects on action potential parameters.
How CRISPR Can Be Used to Study GO:0098906 regulation of Purkinje myocyte action potential
Knockout
CRISPR knockout of candidate genes such as NOTCH1 or KCNJ2 in Purkinje-like cell models can test their requirement for normal action potential regulation. Loss-of-function models help establish causality between gene activity and electrophysiological phenotype.
Point Mutation
Point mutation knock-in can recreate disease-associated variants, such as those in RYR2 linked to CPVT, to study their impact on Purkinje myocyte action potentials. This approach preserves endogenous regulatory context.
Knock-in
Knock-in of reporter or tagged alleles, for example tagging KCNJ2, allows tracking of channel localization and trafficking in Purkinje cells. This can reveal how regulatory mechanisms affect channel surface expression.
Overexpression
CRISPR-mediated overexpression of genes such as TRPM4 can model gain-of-function states that lead to propagation failure. Overexpression models are useful for studying dominant effects on conduction.
How EDITGENE Supports regulation of Purkinje myocyte action potential Research
Researchers studying regulation of Purkinje myocyte action potential-related genes often need to determine whether a candidate gene is causally involved in electrical phenotype or is merely a bystander. EDITGENE provides CRISPR-based cell model services that enable precise genetic perturbations in cardiac and other cell types, helping to establish causality and mechanism.
Contact EDITGENE today to design your custom CRISPR model for regulation of Purkinje myocyte action potential research.
Frequently Asked Questions About regulation of Purkinje myocyte action potential
What is GO:0098906?
GO:0098906 is the Gene Ontology term for regulation of Purkinje myocyte action potential, defined as any process that modulates the frequency, rate or extent of action potential creation, propagation or termination in a Purkinje myocyte, typically via voltage-gated ion channels.
What genes are involved in regulation of Purkinje myocyte action potential?
Genes include TRPM4, KCNJ2, NOTCH1, CACNA1C, SCN5A, and RYR2, among others, based on their roles in cardiac electrical signaling.
Why is regulation of Purkinje myocyte action potential important?
It ensures proper ventricular activation and its dysregulation can cause arrhythmias such as CPVT, where the Purkinje-myocardial junction is an origin of ventricular arrhythmia.
How is Purkinje myocyte action potential regulated?
It is regulated by ion channel expression and activity, epigenetic mechanisms such as Notch signaling, and cyclic nucleotide pathways.
What diseases are linked to Purkinje myocyte action potential dysregulation?
Diseases include CPVT, conduction block, and channelopathies such as Andersen-Tawil syndrome.
What research methods study Purkinje myocyte action potential?
Methods include patch clamp, voltage clamp, RNA-seq, ChIP-seq, computational modeling, and calcium imaging.
Can CRISPR be used to study Purkinje myocyte action potential?
Yes, CRISPR knockout, knock-in, point mutation, and overexpression models allow causal testing of candidate genes in cardiac cells.
What is the role of TRPM4 in Purkinje myocyte action potential?
TRPM4 overexpression can cause propagation failure, indicating its involvement in conduction regulation.
How does Notch signaling affect Purkinje myocyte action potential?
Notch mediates epigenetic regulation of voltage-gated potassium currents, thereby influencing action potential properties.
What cell models are available for studying regulation of Purkinje myocyte action potential?
iPSC-derived Purkinje-like cells, cardiac conduction cell lines, and CRISPR-engineered cardiomyocytes are commonly used.
Conclusion
GO:0098906, regulation of Purkinje myocyte action potential, is a critical biological process that governs cardiac conduction and arrhythmia susceptibility. The integration of ion channel biology, epigenetic regulation, and signaling pathways defines how Purkinje cells maintain or lose electrical stability. Continued research using CRISPR models and advanced electrophysiology will further elucidate these mechanisms and inform therapeutic strategies.
References
- 1. Sharpee TO et al.. 2016. 25th Annual Computational Neuroscience Meeting: CNS-2016.. BMC Neurosci 17 Suppl 1(Suppl 1):54 PMID: 27534393
- 2. Gaur N et al.. 2019. Propagation Failure by TRPM4 Overexpression.. Biophys J 116(3):469-476 PMID: 30598284
- 3. Katz AM. 1985. Basic cellular mechanisms of action of the calcium-channel blockers.. Am J Cardiol 55(3):2B-9B PMID: 2578725
- 4. Varró A et al.. 1992. The impact of single cell voltage clamp on the understanding of the cardiac ventricular action potential.. Cardioscience 3(3):131-44 PMID: 1384746
- 5. Singh NK et al.. 2024. Multimodal action of phosphodiesterase 5 inhibitors against neurodegenerative disorders: An update review.. J Biochem Mol Toxicol 38(11):e70021 PMID: 39425458
- 6. Li E et al.. 2024. The network of cardiac K(IR)2.1: its function, cellular regulation, electrical signaling, diseases and new drug avenues.. Naunyn Schmiedebergs Arch Pharmacol 397(9):6369-6389 PMID: 38683369
- 7. Blackwell DJ et al.. 2022. The Purkinje-myocardial junction is the anatomic origin of ventricular arrhythmia in CPVT.. JCI Insight 7(3) PMID: 34990403
- 8. Khandekar A et al.. 2016. Notch-Mediated Epigenetic Regulation of Voltage-Gated Potassium Currents.. Circ Res 119(12):1324-1338 PMID: 27697822
